RESEARCH



Domestic water hardness, genetic risk, and distinct phenotypes of cardiovascular disease

Feng Tian^{1†}, Genfeng Yu^{2†}, Mengyuan Yang^{1†}, Ying Sun³, Zihao Gui², Xiaoyu Zhao¹, Ningjian Wang^{3*}, Heng Wan^{2*} and Xuetao Peng^{1*}

Abstract

Aims The study aimed to investigate the association between domestic water hardness and the incidence of AF and the interaction effects between water hardness and genetic susceptibility to incident AF risk. As a secondary objective, its associations with incident heart failure (HF), coronary heart disease (CHD), and stroke were measured.

Methods The UK Biobank is a prospective cohort study comprising over 500,000 participants recruited in the United Kingdom between 2006 and 2010, aged 37 to 73 years. A total of 447,950 participants did not have prevalent AF, and 423,946 participants who were free of HF, CHD, and stroke at baseline were included. Water hardness was assessed by CaCO₃ concentration. The genetic risk score for AF was based on the standard polygenic risk score. Cox proportional hazards regression models and restricted cubic spline (RCS) analysis were conducted.

Results During a median follow-up of 13.74 years, 30,726 (6.86%) individuals were diagnosed with AF for the first time. Compared with those with water hardness \leq 60 mg/L, individuals with domestic water hardness 121–180 mg/L had a 17% lower risk of developing AF (HR 0.83, 95% CI 0.79–0.87), but water hardness of 61-120 mg/L and > 180 mg/L was associated with a higher risk of incident AF (both 1.04, 1.01–1.07). A non-linear relationship between water hardness and incident AF (*P* for non-linear = 0.001) was found. Individuals with water hardness 121-180 mg/L were also significantly associated with a lower risk of incident HF (HR 0.82, 95% CI 0.75–0.89), CHD (HR 0.80, 95% CI 0.76–0.84) and stroke (HR 0.88, 95% CI 0.81–0.95). There were no significant interaction effects between water hardness level and genetic susceptibility to AF, HF, CHD, and stroke risk (all *P* for interaction > 0.05).

 $^{\dagger}\mathrm{Feng}$ Tian, Genfeng Yu and Mengyuan Yang contributed equally to this work.

*Correspondence: Ningjian Wang wnj48@126.com Heng Wan wanhdr@163.com Xuetao Peng pengxuet@163.com

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article are provide a reincluded in the article's Creative Commons licence, unless indicate otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Conclusion Potential U-shaped associations between domestic water hardness and incident AF across varying levels of genetic risk were found. Hard water (121–180 mg/L) may offer the most benefits compared to soft water when considering overall cardiovascular health, including AF, HF, CHD, and stroke.

Keywords Water hardness, Atrial fibrillation, Cardiovascular disease, Genetic risk, UK biobank

Introduction

Atrial fibrillation (AF) is recognized as the predominant clinical cardiac arrhythmia, frequently manifesting as either a cause or a consequence of heart failure (HF) [1]. Both AF and HF, representing two distinct phenotypes of cardiovascular disease (CVD), are linked to an elevated likelihood of cardiovascular complications and mortality, with their prevalence and incidence exhibiting an upward trend globally [2, 3]. Established etiological factors, including lifestyles, genetic predisposition, cardiometabolic factors, etc., only partially account for the population-attributable risk associated with AF [4–6]. Consequently, there is a pressing need to advance our comprehension of the predisposing risk factors for AF, which may facilitate the development of novel preventive interventions.

Water is a common environmental element in daily life, with a growing focus on its effects on health over the past few decades, particularly regarding domestic water hardness, which is measured in terms of calcium carbonate (CaCO₃) equivalents [7–9]. Previous studies reported inconsistent relationships between domestic water hardness and various diseases such as eczema [10], atopic dermatitis [11], and all-cause and multiple-causespecific cancers [9]. The debate regarding the relationship between domestic water hardness and CVD incidence and mortality remains ongoing. A recent meta-analysis indicated a potential 40% reduction in CVD mortality associated with the consumption of hard water [12]. However, among the twenty-five studies included in the meta-analysis, 28% reported no significant relationship between water hardness and CVD prevention and mortality [12].

Previous studies mainly examined the associations of water hardness with coronary heart disease (CHD) and stroke, with limited evidence available on the associations with AF and HF incidence. Additionally, although genome-wide association studies have effectively identified genetic variants linked to various cardiovascular phenotypes, such as AF, HF, CHD, and stroke, there is a lack of understanding regarding the potential interplay between domestic water hardness and genetic predisposition in influencing the risk of these cardiovascular phenotypes.

Using data from the UK Biobank (UKB) large-scale prospective cohort, this study aimed to investigate the potential association between domestic water hardness and incident AF. Additionally, we sought to explore the interaction between water hardness and genetic susceptibility to AF risk. As a secondary objective, we also examined the associations between water hardness and three other cardiovascular phenotypes, including HF, CHD, and stroke.

Methods

Study design and participants

Our study is based on the UK Biobank, a prospective cohort study comprising over 500,000 participants recruited in the United Kingdom between 2006 and 2010, aged 37 to 73 years [13]. A detailed cohort profile and assessment protocol have been published elsewhere [13]. Briefly, data on biological samples, physical measurements, and touch-screen questionnaires were collected at baseline. The UK Biobank study has obtained full ethical approval from the North West Multi-Center Research Ethics Committee, and all the participants provided written informed consent (http://www.ukbiobank.ac.uk/ethic s/) [13]. The last accessed date is 19 December 2022.

Among the 502,417 participants included in the study, 46,760 were excluded due to missing information on water hardness at baseline. Of the remaining, 447,950 participants did not have prevalent AF at baseline, with 433,378 having genetic data for AF. Additionally, 423,946 participants were free of HF, CHD, and stroke at baseline, allowing for an analysis of the association between water hardness and these three cardiovascular phenotypes as a secondary objective, with 385,991 having genetic data for HF, 410,272 having genetic data for CHD, and 410,272 having genetic data for stroke (Supplementary Fig. S1).

Domestic water hardness

Domestic water hardness data were collected 1 year before the start of baseline recruitment (2005) from local water supply companies in England, Wales, and Scotland by the University of Melbourne, which then provided this category to the UK Biobank (Field IDs: 21100; 21101; 21103; 21104; 21105) [9, 10]. Postcodes were allocated to participant-visit instances according to the approximate location. Subsequently, these assigned postcodes served as a connection to the surveyed locations. 450,000 individual analyses conducted by unforbidden drinking water laboratories in the UK revealed that the hardness of water samples ranged from 1 to 477 mg/L as CaCO₃, with a median value of 141.1 mg/L [14]. Water hardness was assessed by CaCO₃ concentration, which in this study was classified in three ways: (i) as a continuous variable, (ii) as a categorical variable, according to the United States Geological Survey (USGS) classification of CaCO₃ concentration into four groups: soft water ($\leq 60 \text{ mg/L}$), moderately hard water (>60, $\leq 120 \text{ mg/L}$), hard water (>120, $\leq 180 \text{ mg/L}$) and very hard water (>180 mg/L) [9]. In addition, calcium (Ca) and magnesium (Mg) were measured at the water supplies.

Ascertainment of incident AF and three other cardiovascular phenotypes

The incident AF and three other cardiovascular phenotypes were identified from the initial manifestation of health outcomes defined by the 3-character International Statistical Classification of Diseases and Related Health Problems 10th Revision code (ICD-10) (category ID in UKB 1712). The incidents of AF, HF, CHD, and stroke were sourced from death registers, primary care facilities, and hospital records. The definitions of these outcomes based on the ICD-10 specifically were I48 for AF, I50 for HF, I20-I24 for CHD, and I60-I64 and I69 for stroke, as previously described [15].

Genetic risk score for AF and three cardiovascular phenotypes

The genetic risk score for AF, CHD, and stroke was based on the standard polygenic risk score (PRS, field ID 26212, 26227, and 26248 in UK Biobank, respectively) supported by external genome-wide association studies data [16]. The PRS for HF was constructed using single-nucleotide polymorphisms (SNPs) associated with HF with genomewide association significance in a genome-wide association study, not including UKB participants [17], and 12 SNPs selected for HF have been reported previously [18]. We further classified participants with high (the highest PRS quartile), intermediate (the middle two PRS quartiles), or low (the lowest PRS) genetic risk. As anticipated, PRS and PRS quartiles showed positive associations with the risk of AF, HF, CHD, and stroke (Supplementary Fig. S2).

Covariates

The covariates and their classification considered in the present study were similar to the previous research [4, 5, 15]: age (year, continuous), sex (men or women), ethnicity (White/others), education (university or college degree/ others), the Townsend Index (a composite measure of socioeconomic deprivation, continuous), smoking status (never or quit smoking, current smoker), target physical activity or not (\geq 150 min/week of moderate intensity, or \geq 75 min/week of vigorous-intensity, or an equivalent combination), healthy diet score (score \geq 4), body mass index (BMI) (continuous), total cholesterol (continuous), ideal HbA1c or not (ideal HbA1c is HbA1c <5.7%), ideal blood pressure or not (BP < 120/<80 mmHg).

Statistical analyses

IBM SPSS Statistics, version 25 (IBM Corporation, Armonk, NY, USA) and R (version 4.2.1) were used to perform the analyses. Statistical significance was defined as a two-tailed P value < 0.05. Characteristics of participants at baseline were summarized as the mean (SD) or median (interquartile range) for continuous variables and numbers (percentages) for categorical variables concerning CaCO₃ levels of domestic water. Characteristics were compared by domestic water CaCO₃ concentration using analysis of variance or Kruskal-Wallis test for continuous variables and Pearson chi-squared test for categorical variables, as appropriate. Follow-up time was calculated from the baseline date to the occurrence of the outcome, death, or the censoring date (19 December 2022), whichever occurred first. Participants who were lost to followup were not included in this study.

Cox proportional hazard models with the followup time as the time scale were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between water hardness and the primary and secondary outcomes. Several confounders were included in the models, namely age at baseline (continuous), sex, ethnicity (white/others), education (university or college degree/others), the Townsend index (continuous), smoking status (never, former, current), ideal physical activity (yes/no), healthy diet score (yes/no), BMI (continuous), total cholesterol (continuous), ideal HbA1c (yes/no), ideal blood pressure (yes/no). If the information on the above covariates was missing, means (normal distribution) or medians (non-normal distribution) were imputed for continuous variables, or a missing indicator approach was used for categorical variables. Furthermore, we employed another adjustment model to further explore the relationship between CaCO₃, Ca, and Mg and four cardiovascular diseases, adjusting for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, and healthy diet score in the Supplementary Fig. S3.

We measured whether genetic susceptibility to AF and the other three cardiovascular phenotypes modified the association between water hardness and disease risk. We first examined whether the PRS (continuous) and PRS categories were positively associated with AF. The interaction analyses were performed using the likelihood ratio test to compare models with and without a cross-product term. *P* values were calculated for the interaction and stratified associations by PRS category. Tests for linear trends were performed by including ordinal categories as a continuous variable in the regression model.

Restricted cubic spline (RCS) analyses were performed using a four-knot (with knots at the 5th, 35th, 65th, and 95th percentiles) restricted cubic spline function to further validate the potential non-linear relationships of water hardness with incident AF, HF, CHD, and stroke.

Moreover, stratified analyses were performed by sex, age (<60 or \geq 60 years), Townsend index tertiles, race, education, ideal HbA1c, smoking status, total cholesterol level [19] (ideal, <5.2 mmol/L; and nonideal, \geq 5.2 mmol/L), BMI (ideal, <25 kg/ m²; and nonideal, \geq 25 kg/m²), ideal blood pressure, ideal physical activity status, and ideal diet. The *P* values for the product terms between the water hardness and the stratification variables were used to estimate the significance of interactions using the likelihood ratio test comparing models.

In the sensitivity analysis, we used three classification methods of $CaCO_3$ to explore the relationship between CaCO3 and four cardiovascular diseases: (1) as a binary variable ($\leq 180 \text{ mg/L}$, > 180 mg/L); (2) as a ternary variable, with cut-off points at 100 and 200 mg/L according to the World Health Organization (WHO) reports [20]; (3) as a quartile variable, with quartiles as cut-off points.

Results

General characteristics of the participants

The baseline characteristics of the study population by the USGS classification of domestic water hardness are presented in Table 1. Of the 447,950 participants (45.07% men; mean age 56.47 years), the proportions of the population with domestic water CaCO₃ levels of \leq 60 mg/L, between > 60 and \leq 120 mg/L, between > 120 and \leq 180 mg/L, and > 180 mg/L at baseline were 39.26%, 21.47%, 6.41%, and 32.86%, respectively. During a median

follow-up of 13.74 years, 30,726 (6.86%) individuals were diagnosed with AF for the first time. Participants who received higher $CaCO_3$ levels of domestic water were more likely to be younger, women, non-White, non-current smokers, better educated, and have ideal physical activity, body mass index, HbA1c, blood pressure, and diet in baseline (*P* for trend < 0.05).

Associations of water hardness with incident AF and other three cardiovascular phenotypes

Estimated associations between water hardness and incident AF are shown from Cox proportional hazard regression models (Fig. 1). After adjustment for confounders, individuals receiving higher CaCO₃ levels (continuous) of domestic water had a higher risk of incident AF and HF and a lower risk of CHD and stroke (Fig. 1). However, using the USGS criteria, individuals with CaCO₃ levels of domestic water between >120 and \leq 180 mg/L had a 17% lower risk of developing AF (HR 0.83, 95% CI 0.79–0.87), a 20% lower risk of developing CHD (HR 0.80, 95% CI 0.76–0.84), an 18% lower risk of developing HF (HR 0.82, 95% CI 0.75-0.89) and a 12% lower risk of developing stroke (HR 0.88, 95% CI 0.81-0.95) compared with those with CaCO₃ levels of ≤ 60 mg/L (Fig. 1). Compared with the individuals with the lowest Ca quartile, those with the highest Ca quartile had a 6% lower risk of developing CHD (HR 0.94, 95% CI 0.92-0.97) and a 10% lower risk of developing stroke (HR 0.90, 95% CI 0.85-0.95). However, individuals with the highest Mg quartile had a 3% higher risk of developing AF (HR 1.03, 95% CI 1.00-1.06),

	All	CaCO ₃ category (using USGS)								
		≤60 mg/L	>60, ≤120 mg/L	> 120, ≤ 180 mg/L	>180 mg/L	Р	P for trend			
n	447,950	175,857	96,172	28,712	147,209					
Age, year	56.47 (8.08)	56.63 (8.05)	56.80 (7.98)	56.22 (7.92)	56.10 (8.20)	< 0.001	< 0.001			
Male gender (%)	201,913 (45.07%)	79,599 (45.26%)	44,366 (46.13%)	12,838 (44.71%)	65,110 (44.23%)	< 0.001	< 0.001			
White (%)	422,661 (94.35%)	169,864 (96.59%)	92,648 (96.34%)	27,569 (96.02%)	132,580 (90.06%)	< 0.001	< 0.001			
University or college degree (%)	143,232 (31.97%)	52465 (29.83%	25,103 (26.10%)	9684 (33.73%)	55,980 (38.03%)	< 0.001	< 0.001			
Townsend deprivation index	-1.26 (3.10)	-1.29 (3.14)	-1.63 (2.82)	-1.82 (2.80)	-0.88 (3.23)	< 0.001	< 0.001			
Cholesterol, mmol/L	5.70 (1.11)	5.71 (1.11)	5.71 (1.11)	5.69 (1.09)	5.70 (1.09)	0.004	0.001			
Body mass index, kg/m ²	27.42 (4.78)	27.55 (4.80)	27.67 (4.76)	27.54 (4.77)	27.06 (4.75)	< 0.001	< 0.001			
Current smoking (%)	47,719 (10.65%)	19,686 (11.19%)	9663 (10.05%)	3057 (10.65%)	15,313 (10.40%)	< 0.001	< 0.001			
Physical activity at goal (%)	194,515 (43.42%)	74,756 (42.51%)	41,417 (43.07%)	12,101 (42.15%)	66,241 (45.00%)	< 0.001	< 0.001			
Ideal HbA1c (%)	336,377 (75.09%)	130,980 (74.48%)	72,539 (75.43%)	22,186 (77.27%)	110,672 (75.18%)	< 0.001	0.034			
Ideal blood pressure (%)	55,166 (12.32%)	20,604 (11.72%)	10,657 (11.08%)	3499 (12.19%)	20,406 (13.86%)	< 0.001	< 0.001			
Healthy diet (%)	238,783 (53.31%)	93,497 (53.17%)	51,420 (53.47%)	15,816 (55.08%)	78,050 (53.02%)	< 0.001	0.014			
Atrial fibrillation (%)	30,726 (6.86%)	12,531 (7.13%)	7059 (7.34%)	1620 (5.64%)	9516 (6.46%)	< 0.001	< 0.001			
Coronary heart disease (%)	33,222 (7.42%)	13,713 (7.80%)	7504 (7.80%)	1743 (6.07%)	10,262 (6.97%)	< 0.001	< 0.001			
Heart failure (%)	11,648 (2.60%)	4727 (2.69%)	2671 (2.78%)	587 (2.04%)	3663 (2.49%)	< 0.001	< 0.001			
Stroke (%)	10,625 (2.37%)	4511 (2.57%)	2375 (2.47%)	614 (2.14%)	3125 (2.12%)	< 0.001	< 0.001			

Participants' characteristics at baseline were summarized as the mean (SD) or median (interquartile range) for continuous variables and numbers (percentages) for categorical variables in terms of CaCO₃ levels of domestic water. Characteristics were compared by CaCO₃ concentrations of domestic water using analysis of variance or the Kruskal-Wallis test for continuous variables as appropriate and using the Pearson chi-square test for categorical variables. HbA1c, hemoglobin A1c

а	AF						^b СНD					
	Variables	Case	N		HR(95% CI)	P for trend	Variables	Case	N		HR(95% CI)	P for trend
	CaCO3,1 sd	30726	447950	-	1.02 (1.00 , 1.03)		CaCO3,1 sd	34334	423946	•	0.98 (0.97 , 0.99)	
	USGS (CaCO3)					0.161	USGS (CaCO3)					<0.001
	≤60 mg/L	12531	175857	÷ .	1.00 (1.00 , 1.00)		≤60 mg/L	14191	165157	÷	1.00 (1.00 , 1.00)	
	>60,≤120 mg/L	7059	96172		- 1.04 (1.01 , 1.07)		>60,≤120 mg/L	7725	90460	· · · · · · · · · · · · · · · · · · ·	1.00 (0.97 , 1.03)	
	>120,≤180 mg/L	1620	28712		0.83 (0.79, 0.87)		>120,≤180 mg/L	1796	27221		0.80 (0.76, 0.84)	
	>180 mg/L	9516	147209	-•	- 1.04 (1.01 , 1.07)		>180 mg/L	10622	141108		0.95 (0.92, 0.97)	
	Ca, 1 sd	30726	447950	•	1.02 (1.01 , 1.03)		Ca, 1 sd	34334	423946	-	0.99 (0.97, 1.00)	
	Ca quartiles, mg/L					0.583	Ca quartiles, mg/L					<0.001
	Q1(≤15)	10156	141098	÷	1.00 (1.00 , 1.00)		Q1(≤15)	11320	132621	÷	1.00 (1.00 , 1.00)	
	Q2(>15,≤42)	8033	111677		1.00 (0.97 , 1.03)		Q2(>15,≤42)	8871	104993	-	0.99 (0.97, 1.02)	
	Q3(>42,≤99)	5496	86361		0.96 (0.93, 0.99)		Q3(>42,≤99)	6277	82523		0.96 (0.93, 0.99)	
	Q4(>99)	7041	108814		1.02 (0.99 , 1.06)		Q4(>99)	7866	103809		0.94 (0.92, 0.97)	
	Mg, 1 sd	30726	447950		1.01 (1.00 , 1.02)		Mg, 1 sd	34334	423946	•	1.01 (1.00 , 1.02)	
	Mg quartiles, mg/L					0.071	Mg quartiles, mg/L					0.028
	Q1(≤2)	9694	138920	· · · ·	1.00 (1.00 , 1.00)		Q1(≤2)	10654	130857	•	1.00 (1.00 , 1.00)	
	Q2(>2,≤4)	7260	101146		- 1.05 (1.01 , 1.08)		Q2(>2,≤4)	8024	95453		1.05 (1.02, 1.08)	
	Q3(>4,≤5)	6794	104313		- 1.04 (1.01, 1.08)		Q3(>4,≤5)	7672	99058		0.99 (0.96 , 1.02)	
	Q4(>5)	6978	103571		- 1.03 (1.00 , 1.06)		Q4(>5)	7984	98578		1.05 (1.02, 1.08)	
			0.7	1	11				0.7	1 1	1	
			0.7	· · · · ·	1.1				0.7	1 1	1	
с							d					
с	HF	•				D.f. and and	d Stroke					D.C.
c	HF Variables	Case	N		HR(95% CI)	P for trend	d Stroke Variables	Case	N		HR(95% CI)	P for trend
c	HF Variables CaCO3,1 sd	Case 12429	N 423946	-	HR(95% CI) 1.01 (1.00 , 1.03)	P for trend	d Stroke Variables CaCO3,1 sd	Case 11040	N 423946	-	HR(95% CI) 0.95 (0.93 , 0.96)	P for trend
c	HF Variables CaCO3,1 sd USGS (CaCO3)	Case 12429	N 423946	-	HR(95% CI) 1.01 (1.00,1.03)	P for trend 0.765	d Stroke Variables CaCO3,1 sd USGS (CaCO3)	Case 11040	N 423946	-	HR(95% CI) 0.95 (0.93 , 0.96)	P for trend <0.001
с	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L	Case 12429 5048	N 423946 165157	+	HR(95% CI) 1.01 (1.00 , 1.03) 1.00 (1.00 , 1.00)	P for trend 0.765	d Stroke Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L	Case 11040 4677	N 423946 165157	-	HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00)	P for trend
с	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L	Case 12429 5048 2841	N 423946 165157 90460	-	HR(95% CI) 1.01 (1.00 , 1.03) 1.00 (1.00 , 1.00) 1.06 (1.01 , 1.11)	P for trend 0.765	d Stroke Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L	Case 11040 4677 2470	N 423946 165157 90460	•	HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L >120,≤180 mg/L	Case 12429 5048 2841 -631	N 423946 165157 90460 27221 —	• •	HR(95% Cl) 1.01 (1.00 , 1.03) 1.00 (1.00 , 1.00) 1.06 (1.01 , 1.11) 0.82 (0.75 , 0.89)	P for trend 0.765	d Variables CaCO3,1 sd USGS (CaCO3) ≤60 rg/L >60,≤120 rg/L >120,≤180 rg/L	Case 11040 4677 2470 644	N 423946 165157 90460 27221		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95)	P for trend <0.001
С	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L >120,≤180 mg/L	Case 12429 5048 2841 -631 3909	N 423946 165157 90460 27221 - 141108	* * *	HR(95% CI) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09)	P for trend 0.765	d Stroke Variables CaCO3,1 sd USGS (CaCO3) <60 mg/L <60,5120 mg/L <120,5180 mg/L <180 mg/L	Case 11040 4677 2470 644 3249	N 423946 165157 90460 27221 141108		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92)	P for trend <0.001
С	HF Variables CaC03,1 sd USGS (CaC03) ≤60 mg/L >120,≤180 mg/L >180 mg/L Ca, 1 sd	Case 12429 5048 2841 -631 3909 12429	N 423946 165157 90460 27221 - 141108 423946	• •	HR(95% Cl) 1.01 (1.00, 1.03) 1.06 (1.01, 1.10) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04)	P for trend 0.765	d Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,5120 mg/L >120,≤180 mg/L >180 mg/L Ca, 1 sd	Case 11040 4677 2470 644 3249 11040	N 423946 165157 90460 27221 141108 423946		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92) 0.95 (0.94 , 0.97)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L	Case 12429 5048 2841 -631 3909 12429	N 423946 165157 90460 27221 - 141108 423946	* * *	HR(95% Cl) 1.01 (1.00 , 1.03) 1.06 (1.01 , 1.11) 0.82 (0.75 , 0.89) 1.05 (1.00 , 1.09) 1.02 (1.00 , 1.04)	P for trend 0.765 0.996	d Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60.s120 mg/L >120.≤180 mg/L Ca, 1 sd Ca quartiles, mg/L	Case 11040 4677 2470 644 3249 11040	N 423946 165157 90460 27221 141108 423946	+ 	HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92) 0.95 (0.94 , 0.97)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >120,≤180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15)	Case 12429 5048 2841 -631 3909 12429 4079	N 423946 165157 90460 27221 – 141108 423946 132621		HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.88) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00)	P for trend 0.765 0.996	d Stroke Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60.5120 mg/L >180 mg/L Ca,1 sd Ca quartiles, mg/L Q1(≤15)	Case 11040 4677 2470 644 3249 11040 3752	N 423946 165157 90460 27221 141108 423946 132621		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92) 0.95 (0.94 , 0.97) 1.00 (1.00 , 1.00)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L >120,≤180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42)	Case 12429 5048 2841 -631 3909 12429 4079 3219	N 423946 165157 90460 27221 – 141108 423946 132621 104993	• •	HR(95% Cl) 1.01 (1.00 , 1.03) 1.00 (1.00 , 1.00) 1.06 (1.01 , 1.11) 0.82 (0.75 , 0.89) 1.05 (1.00 , 1.09) 1.02 (1.00 , 1.04) 1.00 (1.00 , 1.00) 1.02 (0.97 , 1.07)	P for trend 0.765 0.996	d Stroke CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,5120 mg/L >180 mg/L Ca,1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,542)	Case 11040 4677 2470 644 3249 11040 3752 2916	N 423946 165157 90460 27221 141108 423946 132621 104993	+ -+ +	HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >120,≤180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99)	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307	N 423946 165157 90460 27221 141108 423946 132621 104993 82523	• • •	HR(95% Cl) 1.01 (1.00, 1.03) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.97, 1.08)	P for trend 0.765 0.996	d Stroke Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,5120 mg/L >120,≤180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99)	Case 11040 4677 2470 644 3249 11040 3752 2916 1898	N 423946 165157 90460 27221 141108 423946 132621 104993 82523		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92) 0.95 (0.94 , 0.97) 1.00 (1.00 , 1.00) 0.99 (0.95 , 1.04) 0.87 (0.83 , 0.92)	P for trend <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >120,≤120 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99) Q4(>99)	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307 2824	N 423946 165157 90460 27221 – 141108 423946 132621 104993 82523 103809	* * *	HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00) 1.02 (0.97, 1.07) 0.33 (0.97, 1.08) 0.99 (0.95, 1.05)	P for trend 0.765 0.996	d Stroke Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60.120 mg/L >180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99) Q4(>99)	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95)	P for trend <0.001 <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,≤120 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99) Mg, 1 sd	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307 2824 12429	N 423946 165157 90460 27221 – 141108 423946 132621 104993 82523 103809 423946		HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.95, 1.05) 1.03 (1.01, 1.05)	P for trend 0.765 0.996	d Stroke Variables $CaCO3, 1 dd$ USGS (CaCO3) $\leq 60 mg/L$ $> 60, 5120 mg/L$ $> 120, 5180 mg/L$ $Ca, 1 sd$ Ca quartiles, mg/L $C1(\leq 15)$ $C2(>15, 542)$ $C3(>42, \leq 99)$ $C4(>99)$ Mg, 1 sd	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95) 0.99 (0.97, 1.01)	P for trend <0.001 <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,<120 mg/L >180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q3(>42,<59) Q4(>99) Mg, 1 sd Mg quartiles, mg/L	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307 2824 12429	N 423946 165157 90460 27221 – 141108 423946 132621 104993 82523 103809 423946	* * *	HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.00) 1.02 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.97, 1.08) 0.99 (0.95, 1.05) 1.03 (1.01, 1.05)	P for trend 0.765 0.996	d Stroke Variables $CaCO3, 1 sd$ USGS (CaCO3) $\leq 60 mg/L$ $> 60, 5/120 mg/L$ $> 120, 5/180 mg/L$ $> 180 mg/L$ $Ca, 1 sd$ Ca quartiles, mg/L $C1(\leq 15)$, $O2(>15, 542)$ $O3(>42, 599)$ $O4(>99)$ Mg, 1 sd Mg quartiles, mg/L	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95) 0.99 (0.97, 1.01)	P for trend <0.001 <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) \$60 mg/L >120 mg/L >120 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(\$15) Q2(>15,542) Q3(>42,599) Q4(>99) Mg, 1 sd Mg quartiles, mg/L Q1(\$2)	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307 2824 12429 3882	N 423946 165157 90460 27221 – 141108 423946 132621 104993 82523 103809 423946 130857		HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.09) 1.02 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.97, 1.08) 0.99 (0.95, 1.05) 1.03 (1.01, 1.05) 1.00 (1.00, 1.00)	P for trend 0.765 0.996	d Stroke Variables $CaCO3, 1 dd$ USGS (CaCO3) dd USGS (CaCO3) $\leq 60 mg/L$ $> 60, 5120 mg/L$ $> 180 mg/L$ $> 180 mg/L$ $Ca, 1 sd$ Ca quartiles, mg/L $Q1(\leq 15)$ $Q2(>15, 542)$ $Q3(>42, 599)$ $Q4(>99)$ Mg, 1 sd Mg quartiles, mg/L $Q1(\leq 2)$	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040 3532	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857		HR(95% CI) 0.95 (0.93 , 0.96) 1.00 (1.00 , 1.00) 0.98 (0.93 , 1.03) 0.88 (0.81 , 0.95) 0.88 (0.84 , 0.92) 0.95 (0.94 , 0.97) 1.00 (1.00 , 1.00) 0.99 (0.95 , 1.04) 0.87 (0.83 , 0.92) 0.90 (0.85 , 0.95) 0.99 (0.97 , 1.01) 1.00 (1.00 , 1.00)	P for trend <0.001 <0.001 0.901
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >120,≤180 mg/L >180 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(≤15) Q2(>15,≤42) Q3(>42,≤99) Mg, 1 sd Mg quartiles, mg/L Q1(≤2) Q2(>2,≤4)	Case 12429 5048 2841 631 3909 12429 4079 3219 2307 2824 12429 3882 2885	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857 95453		HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.97, 1.07) 1.03 (1.01, 1.05) 1.00 (1.00, 1.00) 1.07 (1.02, 1.12)	P for trend 0.765 0.996 <0.001	d Stroke Variables $CaCO3,1 sd$ USGS (CaCO3) $\leq 60 mg/L$ $> 60,5120 mg/L$ $> 180 mg/L$ $> 180 mg/L$ $> 180 mg/L$ $Ca, 1 sd$ Ca quartiles, mg/L $Q1(\leq 15)$ $Q2(>15,542)$ $Q3(>42,\leq 99)$ Q4(>99) Mg, 1 sd Mg quartiles, mg/L $Q1(\leq 2)$ $Q2(>2,\leq 4)$	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040 3532 2565	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857 95453		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95) 0.99 (0.97, 1.01) 1.00 (1.00, 1.00) 1.03 (0.98, 1.08)	P for trend <0.001 <0.001 0.901
c	HF Variables CaCO3,1 sd USGS (CaCO3) \$60 mg/L >60,5120 mg/L >180 mg/L Ca, 1 sd Ca quartiles, mg/L Q1(5) Q2(>15,542) Q3(>2,542) Mg quartiles, mg/L Q1(\$2) Q2(>2,54) Q3(>4,55)	Case 12429 5048 2841 631 3909 12429 4079 3219 2307 2824 12429 3882 2885 2697	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857 95453 99058		HR(95% C)) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.04) 1.00 (1.00, 1.00) 1.02 (0.97, 1.07) 1.03 (0.97, 1.07) 1.03 (1.01, 1.05) 1.00 (1.00, 1.00) 1.07 (1.02, 1.12) 1.00 (0.95, 1.06)	P for trend 0.765 0.996 <0.001	d Stroke Variables $CaCO3, 1 \text{ sd}$ USGS (CaCO3) $\leq 60 \text{ ng/L}$ $> 60, 5120 \text{ ng/L}$ $> 120, 5180 \text{ ng/L}$ $> 180 \text{ ng/L}$ $Ca, 1 \text{ sd}$ Ca quartiles, ng/L $Q1(\leq 15)$ $Q2(>15, \leq 42)$ $Q3(>42, \leq 99)$ $Q4(>99)$ Mg, 1 sd Mg quartiles, ng/L $Q1(\leq 2)$ $Q2(>2, \leq 4)$ $Q3(>4, \leq 5)$	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040 3532 2565 2377	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857 95453 99058		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95) 0.99 (0.97, 1.01) 1.00 (1.00, 1.00) 1.03 (0.98, 1.08) 0.94 (0.89, 0.99)	P for trend <0.001 <0.001
c	HF Variables CaCO3,1 sd USGS (CaCO3) ≤60 mg/L >60,<120 mg/L >180 mg/L >180 mg/L Ca quartiles, mg/L Q1(<15) Q2(>15,<42) Q3(>42,<59) Mg, 1 sd Mg quartiles, mg/L Q1(<2) Q2(>2,<4) Q3(>4,<55) Q4(>5)	Case 12429 5048 2841 -631 3909 12429 4079 3219 2307 2824 12429 3882 2885 2697 2965	N 423946 165157 90460 27221 – 141108 423946 132621 104993 82523 103809 423946 130857 95453 99058 98578		HR(95% Cl) 1.01 (1.00, 1.03) 1.00 (1.00, 1.00) 1.06 (1.01, 1.11) 0.82 (0.75, 0.89) 1.05 (1.00, 1.09) 1.02 (1.00, 1.09) 1.02 (1.00, 1.00) 1.02 (0.97, 1.08) 0.99 (0.95, 1.05) 1.03 (1.01, 1.05) 1.00 (1.00, 1.00) 1.07 (1.02, 1.12) 1.00 (0.95, 1.06) 1.13 (1.07, 1.18)	P for trend 0.765 0.996 <0.001	d Stroke Variables $CaCO3, 1 sd$ USGS $(CaCO3) \le 60 mg/L > 60.5120 mg/L > 120.5180 mg/L > 180 mg/L Ca, 1 sd Ca quartiles, mg/L C1(≤15) Q2(>15.542) Q3(>42.599) Q4(>99) Mg, 1 sd Mg quartiles, mg/L C1(<2) Q2(>2.5.44) Q3(>4.55) Q4(>5)$	Case 11040 4677 2470 644 3249 11040 3752 2916 1898 2474 11040 3532 2565 2377 2566	N 423946 165157 90460 27221 141108 423946 132621 104993 82523 103809 423946 130857 95453 99058 98578		HR(95% CI) 0.95 (0.93, 0.96) 1.00 (1.00, 1.00) 0.98 (0.93, 1.03) 0.88 (0.81, 0.95) 0.88 (0.84, 0.92) 0.95 (0.94, 0.97) 1.00 (1.00, 1.00) 0.99 (0.95, 1.04) 0.87 (0.83, 0.92) 0.90 (0.85, 0.95) 0.99 (0.97, 1.01) 1.00 (1.00, 1.00) 1.03 (0.98, 1.09) 1.03 (0.98, 1.09)	P for trend <0.001 <0.001 0.901

Fig. 1 Associations of water hardness with AF and three other cardiovascular phenotypes incidence. HR of (a) AF, (b) CHD, (c) HF, and (d) stroke was adjusted for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, healthy diet score, BMI, total cholesterol, ideal HbA1c, and ideal blood pressure. HR, hazard ratio; AF, atrial fibrillation; CHD, coronary heart disease; HF, heart failure; USGS, United States Geological Survey; BMI, body mass index; HbA1c, hemoglobin A1c

a 5% higher risk of developing CHD (HR 1.05, 95% CI 1.02–1.08) and a 13% higher risk of developing HF (HR 1.13, 95% CI 1.07–1.18) (Fig. 1). Furthermore, when only adjusting for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, and healthy diet score, the results are consistent (Supplementary Fig. S3).

Non-linear associations between water hardness with incident AF and other three cardiovascular phenotypes

We utilized non-linear spline models to analyze the estimated associations between domestic water hardness and cardiovascular phenotype outcomes. As illustrated in Fig. 2, the results indicated a non-linear relationship between water hardness and the incidence of AF (*P* for non-linear = 0.001) and a potential non-linear relationship with the incidence of HF (*P* for non-linear = 0.078). Furthermore, domestic water hardness was inversely associated with the incidence of CHD and stroke, and the non-linear association was not found (both *P* for overall < 0.001, *P* for non-linear > 0.1).

Associations of water hardness with incident AF and other three cardiovascular phenotypes across genetic risk status In subgroup analyses, individuals with $CaCO_3$ (>120, ≤ 180 mg/L) had a lower risk of AF among low, intermediate, and high genetic risk groups (Fig. 3a). In addition, we did not observe any interaction between the categories of PRS and $CaCO_3$ (*P* for interaction > 0.4) (Fig. 3a). Similar associations of water hardness with HF, CHD, and stroke across genetic risk status were also observed (Fig. 3b-d).

Stratification analysis on the associations of water hardness with incident AF and other three cardiovascular phenotypes

We further conducted stratified analyses to evaluate whether there was a different association between water hardness and incident AF risk by different risk factor statuses. We found a significant interaction between water hardness and age and HbA1c for incident AF risk (*P* for interaction = 0.017 and 0.019, respectively; Table 2). Among participants aged < 60 or \geq 60 years, those who



Fig. 2 Restricted cubic spline for testing the hypothesis of non-linear correlation between CaCO₃ and incident AF and three other cardiovascular phenotypes. Spline curves represent hazard ratios of (a) AF, (b) CHD, (c) HF, and (d) stroke adjusted for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, healthy diet score, BMI, total cholesterol, ideal HbA1c, and ideal blood pressure. HR, hazard ratio; AF, atrial fibrillation; CHD, coronary heart disease; HF, heart failure; BMI, body mass index; HbA1c, hemoglobin A1c

received CaCO₃ levels of domestic water between > 120 and \leq 180 mg/L had a 23% (HR 0.77, 95% CI 0.70–0.85) and 15% (HR 0.85, 95% CI 0.80–0.90) lower risk of developing AF, respectively. Among participants with ideal HbA1c, those with CaCO₃ (> 120, \leq 180 mg/L) had a 20% (HR 0.80, 95% CI 0.75–0.85) and 10% (HR 0.90, 95% CI 0.82-1.00) lower risk of developing AF in participants with ideal and nonideal HbA1c, respectively (Table 2). A significant interaction between water hardness and age was also found for CHD risk, rather than HF and stroke risk (Supplementary Tables S1–S3). However, we did not find a significant interaction between water hardness and HbA1c for the risk of CHD, HF, and stroke (Supplementary Tables S1–S3).

Sensitivity analyses

In the sensitivity analyses, the associations of CaCO₃ with incident AF and other three cardiovascular phenotypes were further examined using three methods of classification of CaCO₃ (Supplementary Fig. S4). Compared with the individuals with CaCO₃ levels of \leq 180 mg/L, those with CaCO₃ levels > 180 mg/L had a 4% higher risk of developing AF (HR 1.04, 95% CI 1.02–1.07). Similarly, compared with the individuals with the lowest CaCO₃ quartile (\leq 42 mg/L), those with the highest CaCO3 quartile (>253 mg/L) had a 4% higher risk of developing AF (HR 1.04, 95% CI 1.01–1.08). However, compared with the individuals with CaCO₃ levels of < 100 mg/L, those with CaCO₃ levels between \geq 100 and \leq 200 mg/L had a

a AF									^в снр						
Va	riables	Case	N			HR(95% CI)	P for trend	P for interaction	Variables	Case	N		HB(95% CI)	P for trend	P for interaction
Ca	CO3 1 sd								CaCO3_1sd						
04	Low genetic risk	4158	108345		-	1.03/1.0002	1.06)		Low genetic risk	5673	102568		0.97 (0.95 1.00)		
	Intermediate genetic risk	13687	216688			1.02 (1.0002	1 04)		Intermediate genetic risk	16007	205136		0.98 (0.96 0.99)		
	High gonotic rick	11010	109246		E	1.02 (1.001,	02)		High gonotic rick	11461	102569	. 1	0.00 (0.00 , 0.00)		
119	CS (CaCO3)	11010	100345		5	1.01 (0.88 , 1	.03)	0.480	LISGS (CaCO3)	11401	102300		0.80 (0.80 , 0.880)		0.269
100	u gonatia riak						0 127	0.400	Law genetic rick					0.020	0.203
LU	<0 mail	1500	41000		1	1 00 /1 00 1	0.137		co mall	2202	20196	1	1.00 (1.00 - 1.00)	0.020	
	>60 <120 mg/L	097	41090		ī	1.00(1.00, 1	.00)		>60 c120 mg/l	1200	21464	1	- 1.00 (1.00 , 1.00)		
	>100, \$120 mg/L	214	22990	-	-	0.84 (0.72 0	.21)		>100, 3120 mg/L	1200	21404		- 1.02 (0.80 , 1.10)		
	>120, ≤180 mg/L	214	0903	-		0.04 (0.73, 0	47)		>120, ≤180 mg/L	200	0112	-	0.70 (0.62 , 0.79)		
1	> 160 mg/L	1307	3/302		-	1.09(1.01,1	.17)		> Tou mg/L	1010	35140		0.96 (0.90 , 1.02)	-0.004	
Inte	ermediate genetic risk		0.4070		1		0.254		Intermediate genetic risk		20007		4 00 /4 00 4 00	<0.001	
	≤60 mg/L	5538	84870		•	1.00 (1.00 , 1	.00)		≤60 mg/L	6564	/928/		1.00 (1.00 , 1.00)		
	>60, ≤120 mg/L	3184	46885		-	1.04 (1.00 , 1	.09)		>60, ≤120 mg/L	3663	44308	+	1.00 (0.96 , 1.04)		
	>120, ≤180 mg/L	711	14079			0.80 (0.74 , 0	.87)		>120, ≤180 mg/L	866	13281	-	0.82 (0.76, 0.88)		
	>180 mg/L	4254	70854		-	1.05 (1.01 , 1	.09)		>180 mg/L	4914	68260	-	0.94 (0.90 , 0.97)		
Hig	gh genetic risk						0.680		High genetic risk					0.015	
	≤60 mg/L	4814	42453		•	1.00 (1.00 , 1	.00)		≤60 mg/L	4660	39740	•	1.00 (1.00 , 1.00)		
	>60, ≤120 mg/L	2718	23810		+	1.01 (0.97 , 1	.06)		>60, ≤120 mg/L	2591	22356	+	0.99 (0.94 , 1.04)		
	>120, ≤180 mg/L	655	7092		1	0.84 (0.77 , 0	.91)		>120, ≤180 mg/L	626	6577		0.83 (0.76 , 0.90)		
	>180 mg/L	3631	34990		+	1.03 (0.98 , 1	.07)		>180 mg/L	3584	33895		0.96 (0.91 , 0.998))	
				0.5	1	1.5						0.5 1	1.5		
с									d						
с _{НЕ}									d Stroke						
C HF Va	riables	Case	N			HR(95% CI)	P for trend	P for interaction	d Stroke Variables	Case	N		HR(95% CI)	P for trend	P for interaction
C HF Va Ca	riables aCO3, 1 sd	Case	N		:	HR(95% CI)	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd	Case	N	:	HR(95% CI)	P for trend	P for interaction
C HF Va Ca	r iables aCO3, 1 sd Low genetic risk	Case 2575	N 97623	-	-	HR(95% CI)	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk	Case 2055	N 102568	-	HR(95% CI) 0.95 (0.90 , 0.99)	P for trend	P for interaction
C HF Va Ca	riables aCO3, 1 sd Low genetic risk Intermediate genetic risk	Case 2575 5668	N 97623 195361	-		HR(95% CI) 0.98 (0.94 , 1. 1.03 (1.01 , 1.	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk	Case 2055 5210	N 102568 205136	+	HR(95% CI) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99)	P for trend	P for interaction
C HF Va Ca	riables ICO3, 1 sd Low genetic risk Intermediate genetic risk High genetic risk	Case 2575 5668 3045	N 97623 195361 93007	-		HR(95% CI) 0.98 (0.94 , 1, 1.03 (1.01 , 1, 0.99 (0.95 , 1;	P for trend .02) .06) .02)	P for interaction	d Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk High genetic risk	Case 2055 5210 3383	N 102568 205136 102568	+	HR(95% Cl) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.88 , 0.96)	P for trend	P for interaction
C HF Va Ca	riables ICO3, 1 sd Low genetic risk Intermediate genetic risk High genetic risk SGS (CaCO3)	Case 2575 5668 3045	N 97623 195361 93007	-		HR(95% CI) 0.98 (0.94 , 1. 1.03 (1.01 , 1. 0.99 (0.95 , 1.	P for trend .02) .06) .02)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk High genetic risk USGS (CaCO3)	Case 2055 5210 3383	N 102568 205136 102568	+ +	HR(95% CI) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96)	P for trend	P for interaction
C HF Va Ca US Lo	riables ICO3, 1 sd Low genetic risk Intermediate genetic risk High genetic risk SGS (CaCO3) w genetic risk	Case 2575 5668 3045	N 97623 195361 93007			HR(95% CI) 0.98 (0.94 , 1 1.03 (1.01 , 1 0.99 (0.95 , 1	P for trend .02) .06) .02) 0.406	P for interaction	d Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk High genetic risk USGS (CaCO3) Low genetic risk	Case 2055 5210 3383	N 102568 205136 102568	+ + +	HR(95% Cl) 0.95 (0.90, 0.99) 0.96 (0.93, 0.99) 0.93 (0.89, 0.96)	P for trend	P for interaction
C HF Va Ca US Lo	riables ICO3, 1 sd Low genetic risk High genetic risk IGS (CaCO3) w genetic risk S60 mg/L	Case 2575 5668 3045 1056	N 97623 195361 93007 37549	-		HR(95% CI) 0.98 (0.94 , 1 1.03 (1.01 , 1 0.99 (0.95 , 1 1.00 (1.00 , 1	P for trend .02) .06) .02) 0.406 .00)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s50 mg/L	Case 2055 5210 3383 816	N 102568 205136 102568 37838	+	HR(95% CI) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00)	P for trend 0.019	P for interaction
C HF Va Ca US Lo	riables ICO3, 1 sd Low genetic risk High genetic risk SG (CaCO3) w genetic risk ≤60 mg/L >60, s120 mg/L	Case 2575 5668 3045 1056 607	N 97623 195361 93007 37549 20947	-		HR(95% CI) 0.98 (0.94 , 1, 1.03 (1.01 , 1, 0.99 (0.95 , 1, 1.00 (1.00 , 1, 1.06 (0.96 , 1,	P for trend 00) 00) 02) 0.406 00) 18)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >60, s120 mg/L	Case 2055 5210 3383 816 463	N 102568 205136 102568 37838 21279	-	HR(95% CI) 0.95 (0.90 , 0.99) 0.95 (0.93 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 1.02 (0.91 , 1.14)	P for trend 0.019	P for interaction
C HF Va Ca US Lo	riables CC03, 1 sd Low genetic risk Intermediate genetic risk SGS (CaCO3) w genetic risk ≤60 mg/L >60, ≤120 mg/L >120, s180 mg/L	Case 2575 5668 3045 1056 607 118	N 97623 195361 93007 37549 20947 6280	-		HR(95% CI) 0.98 (0.94, 1. 1.03 (1.01, 1. 0.99 (0.95, 1. 1.00 (1.00, 1. 1.06 (0.96, 1. 0.73 (0.60, 0.	P for trend 02) 06) 02) 0.406 00) 18) 88)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s50 mg/L >60, s120 mg/L >120, 5180 mg/L	Case 2055 5210 3383 816 463 127	N 102568 205136 102568 37838 21279 6678	+ + + + + + + + + + + + + + + + + + + +	HR(95% Cl) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 0.90 (0.75 , 1.09)	P for trend 0.019	P for interaction
C HF Va Ca US Lo	riables tCO3, 1 sd Low genetic risk High genetic risk SGS (CaCO3) w genetic risk ≤60 mg/L ≥0, ≤120 mg/L >120, 5180 mg/L >180 mg/L	Case 2575 5668 3045 1056 607 118 794	N 97623 195361 93007 37549 20947 6280 32847	- - -		HR(95% CI) 0.98 (0.94, 1 1.03 (1.01, 1 0.99 (0.95, 1 1.00 (1.00, 1 1.06 (0.96, 1 0.73 (0.60, 0 0.99 (0.90, 1	P for trend 002 0.406 00 18 88 0.9	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >120, 5180 mg/L >180 mg/L	Case 2055 5210 3383 816 463 127 649	N 102568 205136 102568 37838 21279 6678 36773	+++	HR(95% CI) 0.95 (0.90, 0.99) 0.95 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) - 1.02 (0.91, 1.14) - 0.90 (0.75, 1.09) 0.89 (0.80, 0.99)	P for trend	P for interaction
C HF Va Ca US Lo	riables ICO3, 1 sd Low genetic risk Intermediate genetic risk High genetic risk SGS (CaCO3) w genetic risk s60 mg/L >120 mg/L >120 mg/L >180 mg/L	Case 2575 5668 3045 1056 607 118 794	N 97623 195361 93007 37549 20947 6280 32847			HR(95% CI) 0.98 (0.94 , 1, 1.03 (1.01 , 1, 0.99 (0.95 , 1, 1.00 (1.00 , 1, 1.06 (0.96 , 1, 0.73 (0.60 , 0, 0.99 (0.90 , 1,	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >60, 5120 mg/L >180 mg/L Intermediate genetic risk	Case 2055 5210 3383 816 463 127 649	N 102568 205136 102568 37838 21279 6678 36773	•	HR(95% CI) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 0.90 (0.75 , 1.09) 0.89 (0.80 , 0.99)	P for trend 0.019 0.002	P for interaction
C HF Va Ca US Lo	riables (CO3, 1 sd Low genetic risk High genetic risk SSG (CaCO3) w genetic risk ≤60 mg/L >60, ≤120 mg/L >120, ≤180 mg/L >180 mg/L ermediate genetic risk ≤60 mg/L	Case 2575 5668 3045 1056 607 118 794 2241	N 97623 195361 93007 37549 20947 6280 32847 76071	- - -		HR(95% CI) 0.98 (0.94 , 1 1.03 (1.01 , 1 0.99 (0.95 , 1 1.00 (1.00 , 1 1.06 (0.96 , 1 0.73 (0.60 , 0 0.99 (0.90 , 1 1.00 (1.00 , 1	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk S60 mg/L >120, 5180 mg/L >120, 5180 mg/L Netremediate genetic risk S60 mg/L	Case 2055 5210 3383 816 463 127 649 2155	N 102568 205136 102568 37838 21279 6678 36773 79261	+••	HR(95% CI) 0.95 (0.90, 0.99) 0.96 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) - 1.02 (0.91, 1.14) - 0.90 (0.75, 1.09) 0.89 (0.80, 0.99) 1.00 (1.00, 1.00)	P for trend 0.019 0.002	P for interaction 0.713
C HF Va Ca US Lo	riables ICO3, 1 sd Low genetic risk High genetic risk SGS (CaCO3) w genetic risk s60 mg/L s60, s120 mg/L >120, s180 mg/L >180 mg/L s60, s120 mg/L s60, s120 mg/L s60, s120 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316	N 97623 195361 93007 37549 20947 6280 32847 76071 42231			HR(95% CI) 0.98 (0.94, 1 1.03 (1.01, 1 0.99 (0.95, 1 1.00 (1.00, 1 1.06 (0.96, 1 0.73 (0.60, 0 0.99 (0.90, 1 1.00 (1.00, 1	P for trend (02) (06) (02) (0406 (00) (0406 (00) (043 (00) (15)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >120, s180 mg/L >180 mg/L Intermediate genetic risk s60 mg/L >120 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183	N 102568 205136 102568 37838 21279 6678 36773 79261 44374	•••	HR(95% CI) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 1.02 (0.91 , 1.14) - 0.90 (0.75 , 1.09) 0.89 (0.80 , 0.99) 1.00 (1.00 , 1.00) 0.99 (0.82 , 1.07)	P for trend 0.019 0.002	P for interaction
C HF Va Ca US Lo	riables (CO3, 1 sd Low genetic risk High genetic risk SGS (CaCO3) w genetic risk SG0 (rag(2)) >60, s120 mg/L >120, s180 mg/L >180 mg/L ermediate genetic risk s60 mg/L >120 mg/L >120 mg/L >120 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686			HR(95% C)) 0.98 (0.94 , 1 1.03 (1.01 , 1 0.99 (0.95 , 1 1.00 (1.00 , 1 1.06 (0.96 , 1 0.73 (0.60 , 0 0.99 (0.90 , 1 1.00 (1.00 , 1 1.07 (1.00 , 1 0.82 (0.72 , 0	P for trend 02) 03) 0406 0406 000 18) 88 80 009 000 15) 93)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >100 s120 mg/L >180 mg/L Intermediate genetic risk s50 mg/L >60, s120 mg/L >60, s120 mg/L >60, s120 mg/L 20, s120 mg/L >60, s120 mg/L >60, s120 mg/L 20, s120 mg/L >61, s120 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342	+++++++++++++++++++++++++++++++++++++++	HR(95% Cl) 0.95 (0.90, 0.99) 0.96 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) - 1.02 (0.91, 1.14) - 0.90 (0.75, 1.09) 0.89 (0.80, 0.99) 1.00 (1.00, 1.00) 0.99 (0.92, 1.07) 0.89 (0.82, 1.07)	P for trend 0.019 0.002	P for interaction
C HF Va Ca Lo Int	riables ICO3, 1 sd Low genetic risk High genetic risk SGS (CaCO3) w genetic risk s60 mg/L >60, s120 mg/L >180 mg/L ermediate genetic risk s60 mg/L >60, s120 mg/L >180, s120 mg/L >180, s120 mg/L >180 mg/L >180 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686 64373			HR(95% Cl) 0.98 (0.94, 1, 1.03 (1.01, 1, 0.99 (0.95, 1, 1.00 (1.00, 1, 1.06 (0.96, 1, 0.73 (0.60, 0, 0.99 (0.90, 1, 1.00 (1.00, 1, 1.07 (1.00, 1, 0.82 (0.72, 0, 1.09 (1.03, 1) 0.91 (1.03, 1)	P for trend 02) 06) 02) 0,406 00) 18) 0,043 00, 0,043 00) 15) 93) 16)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >120, 5180 mg/L >120, 5180 mg/L ≥60, 5120 mg/L ≥60, 5120 mg/L ≥120, 5180 mg/L ≥120, 5180 mg/L ≥120 mg/L >120, 5180 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159	+++++++++++++++++++++++++++++++++++++++	HR(95% C1) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.93 (0.89 , 0.96) 	P for trend 0.019 0.002	P for interaction
C HF Va Ca US Lo Int	riables ricO3, 1 sd Low genetic risk Intermediate genetic risk SGS (CaCO3) w genetic risk SGO mg/L >60, s120 mg/L >120, s180 mg/L >60, s120 mg/L >120, s180 mg/L >120, s180 mg/L >120, s180 mg/L >180 eng/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686 64373			HR(95% CI) 0.98 (0.94, 1 1.03 (1.01, 1 0.99 (0.95, 1 1.06 (0.96, 1 0.73 (0.60, 0 0.99 (0.90, 1 1.07 (1.00, 1 1.07 (1.00, 1 0.82 (0.72, 0 1.09 (1.03, 1	P for trend 02) 03) 0406 000 18) 888 000 0.043 000 15) 93) 16) 0.202	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >60, s120 mg/L >180 mg/L Intermediate genetic risk s60 mg/L >180 mg/L >60, s120 mg/L >180 mg/L >180 mg/L >180 mg/L >180 mg/L >180 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159	+++++++++++++++++++++++++++++++++++++++	HR(95% Cl) 0.95 (0.90 , 0.99) 0.96 (0.03 , 0.99) 0.93 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 1.02 (0.91 , 1.44) - 0.90 (0.75 , 1.09) 0.89 (0.80 , 0.99) 1.00 (1.00 , 1.00) 0.99 (0.92 , 1.07) 0.88 (0.78 , 0.99) 0.91 (0.85 , 0.97)	P for trend 0.019 0.002	P for interaction
C HF Va Ca Lo Int	riables tCO3, 1 sd Low genetic risk High genetic risk SGS (CaCO3) w genetic risk ≤60 mg/L >120, 5180 mg/L >180 mg/L armediate genetic risk ≤60 mg/L ≥00, 5120 mg/L >180 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823 1249	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686 64373 35898			HR(95% Cl) 0.98 (0.94, 1, 1.03 (1011, 1, 0.99 (0.95, 1, 1.06 (1.00, 1, 1.06 (0.96, 1, 0.73 (0.80, 0, 0.99 (0.90, 1, 1.07 (1.00, 1, 0.82 (0.72, 0, 1.09 (1.00, 1, 1.09 (1.00, 1, 1.09 (1.00, 1,	P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk ≤80 mg/L >120, 5180 mg/L >120, 5180 mg/L Intermediate genetic risk ≤60 mg/L >120, 5180 mg/L 110 mg/L >120, 5180 mg/L High genetic risk ≤60 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569 1497	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159 41114	+++++++++++++++++++++++++++++++++++++++	HR(95% C1) 0.95 (0.90, 0.99) 0.95 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) 1.02 (0.91, 1.14) - 0.90 (0.75, 1.09) 0.89 (0.80, 0.99) 1.00 (1.00, 1.00) 0.99 (0.92, 1.07) 0.88 (0.78, 0.99) 0.91 (0.85, 0.97) 1.00 (1.00, 1.00)	P for trend 0.019 0.002 <0.001	P for interaction
С HF Va Ca Lo Int	riables ICO3, 1 sd Low genetic risk High genetic risk Intermediate genetic risk 560 (CaCO3) w genetic risk ≤60 mg/L ≥10, s180 mg/L ≥60 s120 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823 1249 703	N 97623 195361 93007 37549 20947 6280 32847 76071 12686 64373 35898 19936			HR(95% CI) 0.98 (0.94, 1. 1.03 (10.11, 1. 0.99 (0.95, 1. 1.00 (1.00, 1. 1.05 (0.96, 1. 0.73 (0.60, 0. 0.99 (0.90, 1. 1.00 (1.00, 1. 1.00 (1.00, 1. 1.07 (1.00, 1. 1.07 (1.00, 1. 1.00 (1.00, 1.00) (1.00, 1.00) (1.00, 1.00) (1.00, 1.00) (1.00, 1.00) (1.00, 1.00) (1.00, 1.00) (P for trend	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk Intermediate genetic risk High genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >100 mg/L Netwerdiate genetic risk s60 mg/L >100 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569 1497 760	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159 41114 22475	• • • • • • • • • • • • • • • • • • • •	HR(95% Cl) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.53 (0.89 , 0.96) 1.00 (1.00 , 1.00) - 0.90 (0.75 , 1.09) 0.89 (0.80 , 0.99) 1.00 (1.00 , 1.00) 0.99 (0.82 , 1.07) 0.88 (0.78 , 0.99) 0.91 (0.85 , 0.97) 1.00 (1.00 , 1.00) 0.94 (0.85 , 0.97)	P for trend 0.019 0.002 <0.001	P for interaction
C HF Va Ca US Lo Int	riables (CO3, 1 sd Low genetic risk High genetic risk SSG (CaCO3) ≈60 mg/L ≈60, ≤120 mg/L ≈120, ≤180 mg/L ≈180 mg/L ≈180 mg/L ≈120, ≤180 mg/L ≈120, ≤180 mg/L ≈180 mg/L ≈180 mg/L ≈180 mg/L ≈180 mg/L ≈180 mg/L ≈120, s180 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L ≈120 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823 1249 703 165	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686 64373 35898 19936	- 		HR(95% Cl) 0.98 (0.94 , 1, 1.03 (1.01 , 1, 0.99 (0.95 , 1, 1.00 (1.00 , 1, 1.06 (0.96 , 1, 0.73 (0.80 , 0, 0.99 (0.90 , 1, 1.07 (1.00 , 1, 0.82 (0.72 , 0, 1.09 (1.03 , 1, 1.00 (1.00	P for trend 02) 03) 0406 0406 0406 0406 0403 00 15) 00 15) 15) 00 00 15) 15) 00 15) 15) 15) 10 10 10 10 10 10 10 10 10 10	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk S60 mg/L >120, 5180 mg/L >120, 5180 mg/L >120, 5180 mg/L >120, 5180 mg/L >180 mg/L High genetic risk s60 mg/L >180 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569 1497 760 197	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159 41114 22475 6610		HR(95% Cl) 0.95 (0.90, 0.99) 0.96 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) - 1.02 (0.91, 1.14) - 0.96 (0.75, 1.09) 0.89 (0.80, 0.99) 1.00 (1.00, 1.00) 0.99 (0.92, 1.07) 0.89 (0.78, 0.99) 0.91 (0.85, 0.97) 1.00 (1.00, 1.00) 0.94 (0.86, 1.02) 0.87 (0.74, 0.94)	P for trend 0.019 0.002 <0.001	P for interaction
C HF Va Ca US Lo Int	riables ICO3, 1 sd Low genetic risk High genetic risk High genetic risk S66 (CaCO3) w genetic risk ≤60 mg/L >120, s180 mg/L >120, s180 mg/L >120, s180 mg/L >120, s180 mg/L >180 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823 1249 703 165 928	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 12686 64373 35898 19936 6129			HR(95% CI) 0.98 (0.94, 1, 1.03 (1.01, 1, 0.99 (0.95, 1, 1.06 (0.96, 1, 0.73 (0.60, 0, 0.99 (0.90, 1, 1.00 (1.00, 1, 1.07 (1.00, 1, 1.07 (1.00, 1, 1.07 (1.00, 1, 1.00 (1.00, 1, 1.00 (1.00, 1, 1.01 (0.82, 1, 0.79 (0.67, 0, 0.79 (0.67, 0, 0.77 (0.67, 0, 0, 0.77 (0.67, 0, 0.77 (0.67, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,	P for trend (2) (6) (1) (1) (1) (1) (1) (1) (1) (1	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk High genetic risk USSG (CaCO3) Low genetic risk s60 mg/L >100 mg/L >100 mg/L Netwendiate genetic risk s60 mg/L >100 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569 1497 760 197 929	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159 41114 22475 6610 32369	+++++++++++++++++++++++++++++++++++++++	HR(95% Cl) 0.95 (0.90 , 0.99) 0.96 (0.93 , 0.99) 0.53 (0.89 , 0.96) 1.00 (1.00 , 1.00) 1.02 (0.91 , 1.41) - 0.90 (0.75 , 1.09) 0.89 (0.80 , 0.99) 1.00 (1.00 , 1.00) 0.99 (0.92 , 1.07) 0.88 (0.78 , 0.99) 0.91 (0.85 , 0.97) 1.00 (1.00 , 1.00) 0.94 (0.86 , 1.02) 0.85 (0.74 , 0.99) 0.83 (0.77 , 0.99) 0.83 (0.79 , 0.99) 0.83 (0.77 ,	P for trend 0.019 0.002 <0.001	P for interaction
^C HF Va Ca US Lo Int	riables (CO3, 1 ad Low genetic risk High genetic risk SGS (CaCO3) se0 mg/L >60, 9120 mg/L >180 mg/L >180 mg/L >180 mg/L >120, 5180 mg/L >180 mg/L >120, s180 mg/L >120, s180 mg/L >120, s180 mg/L >120 mg/L >120 mg/L >120 mg/L >120 mg/L >120 mg/L	Case 2575 5668 3045 1056 607 118 794 2241 1316 288 1823 1249 703 165 928	N 97623 195361 93007 37549 20947 6280 32847 76071 42231 42231 42686 64373 35898 19936 6129 31044	- - -		HR(95% Cl) 0.98 (0.94 , 1 1.03 (1.01 , 1 0.99 (0.95 , 1 1.00 (1.00 , 1 1.00 (0.96 , 1 0.73 (0.80 , 0 0.99 (0.90 , 1 1.00 (1.00 , 1 1.07 (1.00 , 1 0.82 (0.72 , 0 0.82 (0.72 , 0 1.09 (1.03 , 1 1.01 (0.92 , 1 0.79 (0.87 , 0 0.97 (0.89 , 1) 0.97 (0.89 , 1)	P for trend 00) 00) 00) 18) 18) 000 15) 15) 15) 000 15) 000 15) 000 15) 000 15) 000 15) 000 15) 000 15) 000 15) 000 15) 15) 15) 15) 15) 15) 15) 15)	P for interaction	d Stroke Variables CaCO3, 1sd Low genetic risk High genetic risk USGS (CaCO3) Low genetic risk USGS (CaCO3) Low genetic risk s60 mg/L >100, s120 mg/L >180 mg/L	Case 2055 5210 3383 816 463 127 649 2155 1183 303 1569 1497 760 197 929	N 102568 205136 102568 37838 21279 6678 36773 79261 44374 13342 68159 41114 22475 6610 32369		HR(95% Cl) 0.95 (0.90, 0.99) 0.96 (0.93, 0.99) 0.93 (0.89, 0.96) 1.00 (1.00, 1.00) - 1.02 (0.91, 1.14) - 0.90 (0.75, 1.09) 0.89 (0.80, 0.99) 1.00 (1.00, 1.00) 0.99 (0.82, 1.07) 0.89 (0.82, 1.07) 0.81 (0.85, 0.97) 1.00 (1.00, 1.00) 0.94 (0.86, 1.02) 0.83 (0.77, 0.90)	P for trend 0.019 0.002 <0.001	P for interaction

Fig. 3 Multivariable-adjusted HRs (95%Cls) of incident AF and three other cardiovascular phenotypes associated with CaCO₃ (continuous and categorical) stratified by genetic risk. HR of (a) AF, (b) CHD, (c) HF, and (d) stroke was adjusted for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, healthy diet score, BMI, total cholesterol, ideal HbA1c, and ideal blood pressure. HR, hazard ratio; AF, atrial fibrillation; CHD, coronary heart disease; HF, heart failure; BMI, body mass index; HbA1c, hemoglobin A1c

10% lower risk of developing AF (HR 0.90, 95% CI 0.86– 0.94), and those with $CaCO_3$ levels > 200 mg/L had a 3% higher risk of developing AF (HR 1.03, 95% CI 1.00-1.05).

Discussion

In this large-scale cohort with an over 10-year follow-up time, the following were observed: (i) using the USGS criteria, individuals with $CaCO_3$ levels of domestic water (>120, \leq 180 mg/L) had a lower risk of developing AF, HF, CHD, and stroke. (ii) Non-linear relationships were identified between domestic water hardness and the incidence of AF and HF. (iii) The associations between water hardness and the four phenotypes of CVDs, including AF, HF, CHD, and stroke, remained significant across varying levels of genetic risk.

Few studies evaluated the association between domestic hard water and the incidence of AF, although previous studies predominantly concentrated on the relationships between domestic water hardness and CVD mortality. A recent meta-analysis demonstrated a significant correlation between total water hardness and a protective effect against CVD mortality [12]. However, few large-scale cohort studies explored the associations between water hardness and the incidence of CVD. One case-control study involving 1,021 individuals suggested a protective role of hard water consumption in the incidence of CVD without considering phenotypic variations [21]. Additionally, an ecological study reported an inverse relationship between water hardness and the incidence of CHD [22]. Our study builds upon these previous findings by identifying an inverse and linear association between water hardness and the incidence of CHD and stroke. Furthermore, we disclosed U-shaped relationships between water hardness and the incidence of AF and HF, indicating a potentially beneficial association with hard water (>120, \leq 180 mg/L).

As far as we know, this study is the first to investigate the interaction between water hardness and the PRS on incident AF. Our findings revealed that participants exposed to hard water (>120, \leq 180 mg/L) had the lowest risk of incident AF across different levels of genetic risk. Similar results were also observed regarding the risk of incident HF and CHD. These results indicate that hard water exposure may benefit various cardiovascular conditions, such as AF, HF, and CHD, irrespective of genetic predisposition, if the observed associations are causal. However, in stratified analyses, significant interaction effects of age on the associations between water hardness and incident AF and CHD were identified. The protective effect of hard water (>120, \leq 180 mg/L) on

Table 2 Stratification analysis on the associations of water hardness with incident AF

	CaCO ₃ cate	gory (using USGS)	P for trend	P for interaction		
	≤60 mg/L	>60, ≤120 mg/L	>120, ≤180 mg/L	> 180 mg/L	_	
Sex ^a						
Women	Ref.	1.04 (0.99, 1.09)	0.84 (0.77, 0.91)	1.08 (1.03, 1.13)	0.011	0.222
Men	Ref.	1.04 (1.00, 1.08)	0.82 (0.77, 0.88)	1.02 (0.98, 1.05)	0.813	
Age						
<60	Ref.	1.03 (0.98, 1.09)	0.77 (0.70, 0.85)	0.99 (0.94, 1.04)	0.169	0.017
≥60	Ref.	1.04 (1.01, 1.08)	0.85 (0.80, 0.90)	1.06 (1.03, 1.09)	0.015	
Townsend deprivation index						
Tertile 1	Ref.	1.07 (1.02, 1.13)	0.83 (0.77, 0.91)	1.07 (1.02, 1.13)	0.08	0.216
Tertile 2	Ref.	1.03 (0.98, 1.08)	0.80 (0.73, 0.87)	1.05 (1.01, 1.10)	0.214	
Tertile 3	Ref.	1.02 (0.97, 1.08)	0.86 (0.78, 0.95)	1.01 (0.97, 1.06)	0.949	
Race ^a						
White	Ref.	1.04 (1.01, 1.07)	0.83 (0.78, 0.87)	1.04 (1.01, 1.07)	0.167	0.704
others	Ref.	0.91 (0.73, 1.14)	0.95 (0.68, 1.33)	1.07 (0.91, 1.26)	0.214	
Education ^a						
University or college degree	Ref.	1.05 (0.99, 1.12)	0.84 (0.76, 0.93)	1.03 (0.98, 1.09)	0.616	0.77
Others	Ref.	1.04 (1.00, 1.07)	0.82 (0.77, 0.87)	1.05 (1.02, 1.09)	0.087	
HbA1c ^a						
Ideal	Ref.	1.04 (1.00, 1.08)	0.80 (0.75, 0.85)	1.04 (1.00, 1.07)	0.516	0.019
Nonideal	Ref.	1.01 (0.95, 1.07)	0.90 (0.82, 1.00)	1.02 (0.96, 1.07)	0.841	
Smoking ^a						
Ideal	Ref.	1.05 (1.01, 1.08)	0.83 (0.78, 0.88)	1.05 (1.02, 1.08)	0.071	0.257
Nonideal	Ref.	0.97 (0.89, 1.06)	0.82 (0.71, 0.96)	1.01 (0.93, 1.09)	0.797	
Cholesterol						
Ideal	Ref.	1.05 (1.00, 1.10)	0.82 (0.75, 0.89)	1.04 (0.99, 1.08)	0.546	0.786
Nonideal	Ref.	1.03 (0.99, 1.07)	0.84 (0.78, 0.89)	1.04 (1.01, 1.08)	0.181	
BMI						
Ideal	Ref.	1.02 (0.95, 1.08)	0.77 (0.69, 0.86)	0.98 (0.93, 1.04)	0.199	0.253
Nonideal	Ref.	1.05 (1.01, 1.08)	0.84 (0.80, 0.89)	1.05 (1.02, 1.09)	0.046	
Blood pressure ^a						
Ideal	Ref.	0.99 (0.87, 1.14)	0.94 (0.76, 1.17)	0.93 (0.82, 1.04)	0.177	0.354
Nonideal	Ref.	1.04 (1.01, 1.07)	0.82 (0.78, 0.87)	1.05 (1.02, 1.08)	0.081	
Physical activity ^a						
Ideal	Ref.	1.04 (1.00, 1.09)	0.87 (0.80, 0.94)	1.05 (1.01, 1.09)	0.106	0.535
Nonideal	Ref.	1.02 (0.97, 1.07)	0.79 (0.73, 0.87)	1.02 (0.98, 1.07)	0.947	
Diet ^a						
Ideal	Ref.	1.04 (1.00, 1.09)	0.83 (0.77, 0.89)	1.05 (1.01, 1.09)	0.155	0.784
Nonideal	Ref.	1.03 (0.99, 1.08)	0.82 (0.76, 0.89)	1.03 (0.99, 1.08)	0.514	

Model: adjusted for age, sex, ethnicity, education, the Townsend index, smoking status, ideal physical activity, healthy diet score, BMI, total cholesterol, ideal HbA1c, and ideal blood pressure

In the analysis stratified by marked categorical variable, the corresponding variable was excluded from the model

AF, atrial fibrillation; USGS, United States Geological Survey; BMI, body mass index; HbA1c, hemoglobin A1c

incident AF and CHD was more pronounced in younger individuals. This implies earlier exposure to an optimal water hardness environment may confer greater benefits in preventing AF and CHD. Although women generally have a lower prevalence of atrial fibrillation than men [23], we did not find a significant sex-different association between water hardness and AF, which implies that both women and men were suggested to be exposed to an optimal water hardness environment for preventing AF. Nonetheless, these secondary findings warrant further investigation.

The mechanisms underlying the association between domestic water hardness and the susceptibility to AF are complex and not fully elucidated. The health implications of water hardness are primarily attributed to the presence of dissolved salts, specifically calcium [24, 25]. The physiological impact of calcium ions may elucidate the potential relationship between water hardness and AF risk. The possible explanations were: (I) disrupted intracellular calcium cycling during AF underlies impaired atrial contractility and excitability. During cell depolarization, Ca²⁺ influx via L-type Ca²⁺ channels triggers a substantial release of Ca²⁺ from adjacent sarcoplasmic reticulum (SR) sites through ryanodine receptor 2 (RyR2) channels, driving myocyte contraction [26]. (II) Mechanisms such as Ca²⁺-mediated oxidative stress, inflammatory signaling, and calcium overload contribute to AF development [27]. (III) The decreased corrosive nature of hard water on plumbing systems may contribute to the observed effects on AF by preventing the release of harmful substances such as lead into the water supply [28]. Inversely, as it was reported by WHO, soft water (<100 mg/L) may have a low buffering capacity and so be more corrosive for water pipes [20]. Our results also showed that compared with the individuals with CaCO3 levels of < 100 mg/L, those with CaCO3 levels (between $\ge 100 \text{ and}$ \leq 200 mg/L) had a lower risk of developing AF. Further experimental studies will be needed to verify our findings and reveal the underlying mechanisms.

Meta-analyses had suggested an inverse relationship between dietary magnesium intake and CVD risk [29, 30]. However, the current study presented intriguing findings that elevated magnesium levels in domestic water are associated with a higher risk of AF, CHD, and HF. Similarly, a recent study observed a positive association between magnesium levels in tap water and AF risk [31], aligning with the results of our study. These discrepancies may arise from the substantial differences between dietary magnesium and magnesium intake from tap water. It has been reported that tap water contributes only 2% to the daily magnesium intake among adults aged 55-69 in the Netherlands, where no overall association was found between magnesium in tap water and mortality from ischemic heart disease or stroke [32]. Another prospective study involving men from 24 British towns indicated a positive, rather than inverse, association between magnesium intake from tap water and CHD incidence [33].

The current study has significant implications for public health in the primary prevention of AF and the optimal water hardness for cardiovascular health. A systematic review has indicated distinct risk factors for AF compared to other cardiovascular diseases [34], and recent guidelines have highlighted the limited focus on primary AF prevention [35]. Our findings suggest that hard water (>120, \leq 180 mg/L) may be most beneficial for cardiovascular health, particularly in preventing AF, although previous studies showed increased water hardness was associated with a decreased risk of CHD, stroke, and CVD mortality [12, 36]. In addition, water is a fundamental necessity for sustaining life, and achieving the globally recognized objective of providing safe and managed domestic water would result in significant public health benefits. As water hardness levels exceeding 180 mg/L may elevate the likelihood of developing kidney stones [37], eczema [10], and even all-cause cancer [9], water with a hardness level between >120 and \leq 180 mg/L may be the most advisable option.

Although the current study has several strengths, such as large-scale sample size and extended follow-up duration, the implementation of standardized data collection protocols, and diverse resources for disease diagnosis, certain limitations persist. First, measurements of domestic water hardness were conducted before the baseline, raising concerns about the potential for exposure level fluctuations over time due to variables such as alterations in water sources and treatment procedures or missing information on participants relocating to different addresses, potentially influencing our risk estimates. Second, the lack of data on other water contaminants within the UK Biobank, such as nitrate, metals, and disinfection by-products, restricts the capacity to investigate potential modifications of the association between hard water and cardiovascular phenotypes by these contaminants. Third, the identification of incident cardiovascular phenotypes was based on medical records obtained during follow-up, potentially leading to biased incidences due to the individuals who did not exhibit recorded symptoms. However, it was reported that only about onetenth of AF cases were undiagnosed [15, 38]. Fourth, the study primarily consisted of participants of White British descent from the UK, thereby restricting the generalizability of the results to other races or geographic regions. Fifth, definitive causation cannot be established due to the inherent constraints of observational research. Therefore, further investigation into the underlying causality and mechanisms is warranted.

In summary, the current study observed potential U-shaped associations between domestic water hardness and incident AF and HF across varying levels of genetic risk within the UKB population. Furthermore, higher levels of water hardness may potentially reduce the occurrence of CHD and stroke. When considering overall cardiovascular health, including AF, HF, CHD, and stroke, hard water (>120, ≤180 mg/L) may offer the most benefits compared to soft water. However, further basic research and prospective studies in other populations are necessary to validate these results.

Supplementary Information

The online version contains supplementary material available at https://doi.or g/10.1186/s12940-025-01166-7.

Supplementary Material 1	
Supplementary Material 2	
Supplementary Material 3	
Supplementary Material 4	

Supplementary Material 5

Acknowledgements

We are grateful to the participants of the UK Biobank study, the members of the survey teams, and the project development and management teams.

Author contributions

N.W., H.W. and X.P. conceptualized and revised the manuscript; F.T., G.Y., and M.Y. conducted data analysis and drafted the manuscript; Z.G. and S.Y. verified the results and reviewed the manuscript; H.W. and X.P. assisted with data acquisition and critically revised it for significant intellectual content. All authors approved the final manuscript.

Funding

This work was supported by the Characteristic and Innovative Projects for Regular Higher Education Institutions by the Guangdong Provincial Department of Education (2023WTSCX011), the Higher Education Special Project (Education Reform Category) of the Guangdong Provincial Department of Education (2023GXJK093), and Scientific Research Start Plan of Shunde Hospital, Southern Medical University (SRSP2021019, SRSP2021011). The funding body did not contribute to the study design, data collection, analysis, interpretation, report writing, or decision to submit the paper for publication.

Data availability

The dataset used and analyzed during the current study is available from UK Biobank (www.ukbiobank.ac.uk). This research has been conducted using the UK Biobank Resource under Application Number 77740.

Declarations

Competing interests

The authors declare no competing interests.

Author details

¹Health Management Division, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China

²Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China

³Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China

Received: 2 January 2025 / Accepted: 6 March 2025 Published online: 14 March 2025

References

- 1. Brundel B, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat Reviews Disease Primers. 2022;8(1):21.
- Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation. 2023;148(20):1636–64.
- Writing Committee M, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024;83(1):109–279.
- Sun Y, Zhou Y, Yu B, Zhang K, Wang B, Tan X, Lu Y, Wang N. Frailty, genetic predisposition, and incident atrial fibrillation. Eur Heart J. 2024;45(14):1281–3.
- Sun Y, Yu B, Yu Y, Wang B, Tan X, Lu Y, Wang Y, Zhang K, Wang N. Sweetened beverages, genetic susceptibility, and incident atrial fibrillation: A prospective cohort study. Circulation Arrhythmia Electrophysiol. 2024;17(3):e012145.

- Wang N, Yu Y, Sun Y, Zhang H, Wang Y, Chen C, Tan X, Wang B, Lu Y. Acquired risk factors and incident atrial fibrillation according to age and genetic predisposition. Eur Heart J. 2023;44(47):4982–93.
- Sharrett AR. Water hardness and cardiovascular disease. Circulation. 1981;63(1):A247–50.
- Caro CG, Lever MJ. Water hardness, cardiovascular disease, and nitrate intake. Lancet. 1981;1(8210):50.
- Yang H, Wang Q, Zhang S, Zhang J, Zhang Y, Feng J. Association of domestic water hardness with All-Cause and Cause-Specific cancers: evidence from 447,996 UK biobank participants. Environ Health Perspect. 2024;132(6):67008.
- Lopez DJ, Singh A, Waidyatillake NT, Su JC, Bui DS, Dharmage SC, Lodge CJ, Lowe AJ. The association between domestic hard water and eczema in adults from the UK biobank cohort study. Br J Dermatol. 2022;187(5):704–12.
- Perkin MR, Craven J, Logan K, Strachan D, Marrs T, Radulovic S, Campbell LE, MacCallum SF, McLean WH, Lack G, et al. Association between domestic water hardness, Chlorine, and atopic dermatitis risk in early life: A populationbased cross-sectional study. J Allergy Clin Immunol. 2016;138(2):509–16.
- Bykowska-Derda A, Spychala M, Czlapka-Matyasik M, Sojka M, Bykowski J, Ptak M. The relationship between mortality from cardiovascular diseases and total drinking water hardness: systematic review with Meta-Analysis. Foods 2023, 12(17).
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
- Bao Y, Li Y, Zhou Y, Zhou J, Mu W, Deng X, Shen C, Han L, Ran J. Water quality and neurodegenerative disease risk in the middle-aged and elderly population. Ecotoxicol Environ Saf. 2025;289:117647.
- Wang N, Sun Y, Zhang H, Wang B, Chen C, Wang Y, Chen J, Tan X, Zhang J, Xia F, et al. Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease. Eur Heart J. 2021;42(40):4180–8.
- 16. Thompson DJWD, Selzam S, Peneva I, Moore R, Sharp K. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. *medRxiv* 2022.
- Shah S, Henry A, Roselli C, Lin H, Sveinbjornsson G, Fatemifar G, Hedman AK, Wilk JB, Morley MP, Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163.
- Sun Y, Zhang H, Wang B, Chen C, Chen Y, Chen Y, Xia F, Tan X, Zhang J, Li Q, et al. Joint exposure to positive affect, life satisfaction, broad depression, and neuroticism and risk of cardiovascular diseases: A prospective cohort study. Atherosclerosis. 2022;359:44–51.
- Wang B, Fu Y, Tan X, Wang N, Qi L, Lu Y. Assessing the impact of type 2 diabetes on mortality and life expectancy according to the number of risk factor targets achieved: an observational study. BMC Med. 2024;22(1):114.
- 20. In: Guidelines for drinking-water quality: Fourth edition incorporating the first and second addenda. Geneva; 2022.
- Knezovic NJ, Memic M, Mabic M, Huremovic J, Mikulic I. Correlation between water hardness and cardiovascular diseases in Mostar City, Bosnia and Herzegovina. J Water Health. 2014;12(4):817–23.
- Kousa A, Moltchanova E, Viik-Kajander M, Rytkonen M, Tuomilehto J, Tarvainen T, Karvonen M. Geochemistry of ground water and the incidence of acute myocardial infarction in Finland. J Epidemiol Commun Health. 2004;58(2):136–9.
- Rago A, Pirozzi C, D'Andrea A, Di Micco P, Papa AA, D'Onofrio A, Golino P, Nigro G, Russo V. Gender differences in atrial fibrillation: from the thromboembolic risk to the anticoagulant treatment response. Med (Kaunas) 2023, 59(2).
- 24. Burton A. Hard data for hard water. Environ Health Perspect. 2008;116(3):A114.
- Ferrandiz J, Abellan JJ, Gomez-Rubio V, Lopez-Quilez A, Sanmartin P, Abellan C, Martinez-Beneito MA, Melchor I, Vanaclocha H, Zurriaga O, et al. Spatial analysis of the relationship between mortality from cardiovascular and cerebrovascular disease and drinking water hardness. Environ Health Perspect. 2004;112(9):1037–44.
- Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: A translational perspective. Circul Res. 2020;127(1):51–72.
- Dridi H, Kushnir A, Zalk R, Yuan Q, Melville Z, Marks AR. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Reviews Cardiol. 2020;17(11):732–47.

- Bjorklund G, Dadar M, Chirumbolo S, Aaseth J. High content of lead is associated with the softness of drinking water and Raised cardiovascular morbidity: A review. Biol Trace Elem Res. 2018;186(2):384–94.
- Rosique-Esteban N, Guasch-Ferre M, Hernandez-Alonso P, Salas-Salvado J. Dietary magnesium and cardiovascular disease: A review with emphasis in epidemiological studies. Nutrients 2018, 10(2).
- Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98(1):160–73.
- Wodschow K, Villanueva CM, Larsen ML, Gislason G, Schullehner J, Hansen B, Ersboll AK. Association between magnesium in drinking water and atrial fibrillation incidence: a nationwide population-based cohort study, 2002–2015. Environ Health: Global Access Sci Source. 2021;20(1):126.
- Leurs LJ, Schouten LJ, Mons MN, Goldbohm RA, van den Brandt PA. Relationship between tap water hardness, magnesium, and calcium concentration and mortality due to ischemic heart disease or stroke in the Netherlands. Environ Health Perspect. 2010;118(3):414–20.
- Morris RW, Walker M, Lennon LT, Shaper AG, Whincup PH. Hard drinking water does not protect against cardiovascular disease: new evidence from the British regional heart study. Eur J Cardiovasc Prev Rehabil. 2008;15(2):185–9.
- Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, Perel P, Morley K, Banerjee A, Hemingway H. Are cardiovascular risk factors also

associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837–50.

- Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, et al. 2023 ACC/ AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1–156.
- Gianfredi V, Bragazzi NL, Nucci D, Villarini M, Moretti M. Cardiovascular diseases and hard drinking waters: implications from a systematic review with meta-analysis of case-control studies. J Water Health. 2017;15(1):31–40.
- Bellizzi V, DeNicola L, Minutolo R, Russo D, Cianciaruso B, Andreucci M, Conte G, Andreucci V. Effects of water hardness on urinary risk factors for kidney stones in patients with idiopathic nephrolithiasis. Nephron. 1998;81(Suppl 1):66–70.
- Turakhia MP, Shafrin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, Goldman DP. Estimated prevalence of undiagnosed atrial fibrillation in the united States. PLoS ONE. 2018;13(4):e0195088.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.